Sumanta Kumar Pal, MD
Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma (RCC). For oncologists, the challenge now is to determine which of these combinations will produce optimal results in the setting of intermediate and high-risk disease, according to a panel of experts who discussed the issue in a recent OncLive Peer Exchange®
. In addition, there still appears to be a role for sunitinib among favorable-risk patients. This may be because sunitinib’s role as an angiogenesis inhibitor at this stage in disease progression is more dominant, the panel speculated.
Table 1. Efficacy Data From Phase III Trials Leading to FDA Approval of Checkpoint Inhibitor Combinations in Metastatic RCC
, said. “In our clinics, we use IMDC [International Metastatic Renal Cell Carcinoma Database Consortium] risk criteria to risk stratify our patients and get a sense of who has favorable-risk disease versus intermediate- or poor-risk disease with more guarded prognoses.”
Table 2. FDA Indications and NCCN Recommendations on Use of FDA-Approved Immunotherapy Combinations for Clear Cell Metastatic RCC
... to read the full story